吲哚布芬在急性冠脉综合征患者中使用情况及分析

Application analysis of indobufen in patients with acute coronary syndrome

目的:分析吲哚布芬在急性冠脉综合征(ACS)患者中的临床应用情况及特点。方法:收集2019年7月1日-12月31日期间我院心血管内科的ACS住院患者病历资料,在双联抗血小板治疗(DAPT)中使用吲哚布芬的患者病历79份,采取随机数字表法抽取使用阿司匹林的患者病历79份,对用药情况、药品不良反应及联合用药等进行分析。采用全球急性冠脉事件注册(GRACE)评分、出血危险评估(CRUSADE)评分,评估患者住院期间及出院后短期死亡风险、出血风险。结果:吲哚布芬组与阿司匹林组中年龄≥75岁的患者占比分别为32.9%、27.9%,GRACE评分分别为(114.4±29.2)、(126.3±34.6),CRUSADE评分分别为(36.5±17.4)、(33.2±20.6),出血不良反应发生率分别为5.1%、3.8%,差异均具有统计学意义(P<0.05)。结论:临床制定DAPT方案时,吲哚布芬更适用于高龄、有出血风险的患者,阿司匹林则在有缺血风险患者中应用较多,但缺乏标准化的选药流程,医院需要制定合理选药规则。

Objective:To analyze the clinical application and characteristics of indobufen in patients with acute coronary syndrome(ACS).Methods:79 medical records of patients with ACS who used indobufen as one of the drugs in the double antiplatelet therapy(DAPT)from July 1st,2019 to December 31^(st),2019 were collected from the cardiovascular department of a hospital.Meanwhile,79 medical records of patients with ACS who used aspirin were also collected according to a random number table.The medication,related adverse drug reactions and combined medication of all the patients were retrospectively analyzed.The global registry of acute coronary events(GRACE)score and bleeding risk assessment(CRUSADE)score were used to assess the short-term mortality risk and bleeding risk of all the patients during hospitalization and discharge.Results:The proportion of patients over 75 years old in indobufen group and aspirin group was 32.9%and 27.9%respectively.The GRACE scores were(114.4±29.2)and(126.3±34.6)respectively.The CRUSADE scores were(36.5±17.4)and(33.2±20.6),and the incidence of bleeding events were 5.1%and 3.8%respectively,the differences were statistically significant(P<0.05).Conclusion:When making DAPT plan in clinic,indobufen was more suitable for elderly patients with high bleeding risk while aspirin was more commonly used in patients with high ischemia risk.But there was no standard drug selection process.Hospitals needed to formulate reasonable drug selection rules.